CROSS and PERFECT Trials Preliminary Results

Young-Hak Kim, MD, PhD

Cardiac Institure, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea







Current RCTs for Bifurcation Lesions Evaluation of Optimal Stenting Technique

Trials	Comparison
NORDIC 1	Provisional T vs. Systemic T stenting
NORDIC 2	Crush vs. Culotte
NORDIC 3	Kissing balloon vs. leave alone
BBC	Simple vs. Complex
CACTUS	Provisional T vs. Crush



Lessons From Trials

- No difference in the rate of death, spontaneous
 MI, and repeat revascularization rate
- Superiority of simple stenting in the rate of periprocedural MI

Fewer stents in simple stenting
 <u>BUT</u>, limited by selected inclusion, heterogeneous bifurcations, different procedures, and angiography-guidance





Purposes of Trials


To evaluate the outcomes of different stenting strategies for bifurcation lesions under the guidance of IVUS

To understand the mechanism of acute and chronic compromise of side branch (SB) after bifurcation stenting with use of IVUS and FFR





CROSS & PERFECT Trials



Administration and Sites

Sites

Asan Medical Center Aju University Hospital **Busan Saint Mary's Hospital Busan University Hospital** Catholic University, Kangnam St. Mary's Hospital Chungju Saint Mary's Hospital Chungnam National University Hospital Hallym University Sacred Heart Hospital Kangwon University Hospital Korea Veterans Hospital Kyungsang University Hospital Soonchunhyang University Seoul Hospital Soonchunhyang University Bucheon Hospital Soonchunhyang University Cheonan Hospital **Ulsan University Hospital**

Principle investigator Seung-Jung Park, MD

Sponsor KSCVI, CVRF

Angiographic core lab CVRF

IVUS core lab CVRF

Data management CVRF

Clinical Event Committee CVRF





<u>Choice of optimal stRategy fOr bifurcation leSions</u> with normal Side branch CROSS Trial

Bifurcations without SB Stenosis







Inclusion Criteria

1. Clinical

- Ischemic symptom or sign
- Eligible lesion for intracoronary stenting
- Age >18 years, <75 ages</p>

2. Angiographic

- De novo bifurcation with the MEDINA classification type 1.1.0, 1.0.0, or 0.1.0
- MB: ≥ 2.5 mm, ≥ 50% stenosis, ≤ 50 mm length covered with ≤ 2 stents
- SB: ≥ 2.0 mm, < 50% stenosis</p>






Exclusion Criteria


- Serious comorbidity
- STEMI \leq 2 weeks
- Left main disease
- In-stent restenosis
- Graft vessels
- TIMI flow ≤ grade 2 in the side branch
- Chronic total occlusion
- Renal dysfunction, creatinine \geq 2.0mg/dL








Evaluation of IVUS & FFR to assess the mechanisms of phenomena occurring in bifurcations after stenting



Procedures Single Stent (Provisional T)

Angiographic & Procedural Provisional T Stenting

Performance Performance Sequence Procedure Sequence Procedure TAP 1* MB wiring Done OND TAP 7 * SB rewiring after MB stenting Done ND **TAP 2 *** TAP 8 * SB wiring Done ND Kissing after MB stenting Done O ND TAP 3 * MB predilation Done ND TAP 9 * SB stenting Done ND TAP 4 * SB predilation TAP10 * Done ND Done ND SB balloon dilatation **TAP 5 *** Kissing predilation Done ND TAP 11* MB balloon dilatation Done OND **TAP 6 *** MB stenting Done ND **TAP12*** Final kissing Done ND






Procedures Crush: Classic Stent Crushing

Angiographic & Procedural Classic Crush


Sequence Procedure Performance Sequence Procedure Performance MB stenting Done ND Classic Crush 8 * Classic Crush 1* MB wiring Done OND (Crush SB stent) Classic Crush 2* Done ND Classic Crush 9⁴ SB rewiring SB wiring Done ND SB ballooning by Classic Crush 3 * MB predilation Done ND Classic Crush 10* Done OND small balloon SB high Done ND Classic Crush 11* Classic Crush 4 * SB predilation Done ND pressure dilatation MB high Kissing predilation Classic Crush 5 * Done ND Classic Crush 12^{*} Done O ND pressure dilatation SB stenting Classic Crush 6* Done ND Classic Crush 13* Final kissing dilatation Done ND (MB stent backup) SB balloon and Classic Crush 7 * Done OND wire retrieval



Procedures Crush: Balloon Crushing

Angiographic & Procedural Balloon Crush

Sequence	Procedure	Performance	Sequence	Procedure	Performance
Balloon Crush 1 *	MB wiring	Done OND	Balloon Crush 8 *	MB stenting	Done ND
Balloon Crush 2 *	SB wiring	Done ND	Balloon Crush 9 *	SB rewiring	Done ND
Balloon Crush 3 *	MB predilation	Done OND	Balloon Crush 10 *	SB ballooning by small balloon	Done OND
Balloon Crush 4 *	SB predilation	Done OND	Balloon Crush 11 *	SB high pressure dilatation	Done OND
Balloon crush 5 *	Kissing predilation	Done OND	Balloon Crush 12 *	MB high pressure dilatation	Done OND
Balloon Crush 6 *	SB stenting (MB stent backup)	Done OND	Balloon Crush 13 *	Final kissing dilatation	Done OND
Balloon Crush 7 *	Crush SB stent by MB balloon	Done ND			



CROSS Trial Study Design

Primary end points

- 8-month diameter stenosis in SB

Hypothesis: non-inferiority


- H_a : Leave alone \geq Kissing balloon







Intermediate Stenosis at SB CROSS Patient









Main Branch Stenting Randomized to Endeavor Stent



High pressure dilatation to 4.1mm





Significant SB jail with TIMI 3 flow


- FFR before kissing
- Randomization to kissing balloon














ASAN Medical Center

Final Angiogram





CardioVascular Research Foundation

OPtimal StEnting StRategy For TruE BifurCaTion **PERFECT** Trial

Bifurcations with SB Stenosis



PERFECT Trial Study Design

Primary end point

- 8-month overall angiographic restenosis rate

Hypothesis : non-inferiority - H_a : Provisional T ≥ Crush technique





Inclusion Criteria

1. Clinical


- Ischemic symptom or sign
- Eligible lesion for intracoronary stenting
- Age >18 years, <75 ages</p>

2. Angiographic

- De novo bifurcation with the MEDINA classification type 1.1.1, 1.0.1, or 0.1.1
- MB: \geq 2.5 mm, \geq 50% stenosis, \leq 50 mm length covered with \leq 2 stents
- SB: ≥ 2.0 mm, ≥ 50% stenosis, ≤ 30 mm length covered with 1 stent







Significant Stensis at SB PERFECT Patient












Randomized to Crush





Cypher 3.5 x 28 & 3.0 x 18mm





Final Angiogram










IVUS Finding








9.6 mm, 1 mm/div

CardioVascular Research Foundation



CardioVascular Research Foundation

COLLEGE MEDICINE

Medical Center

Preliminary Results in Intention-to-Treat Principle Baseline Characteristics

	CROSS		PERFECT	
	Kissing (143)	No kissing (145)	Single (191)	Crush (201)
Age, yrs	60.9 ± 9.2	60.9 ± 7.8	60.8 ± 8.8	60.9 ± 9.0
Male	72.0	66.2	75.4	75.1
Diabetics	29.9	29.5	24.5	25.1
Smoking	31.3	23.7	30.9	22.8
Hyperlipidemia	32.8	36.0	40.4	43.9
Hypertension	48.5	52.5	50.5	53.5
Family history	4.5	5.8	9.6	9.1
Prior PCI	5.2	7.9	5.3	8.6
Prior MI	1.5	2.2	3.7	3.0
Renal failure	0.7	0	0.5	0
LV EF, %	61.0 ± 7.6	62.9 ± 5.6	59.2 ± 8.0	60.4 ± 7.2
Sinus rhythm	97.0	97.1	98.4	98.5

Preliminary Results in Intention-to-Treat Principle Baseline Characteristics

	CROSS		PERFECT	
	Kissing (143)	No kissing (145)	Single (191)	Crush (201)
Presentation				
Stable angina	56.0	56.1	63.6	64.3
Unstable angina	36.6	39.6	28.9	32.7
NSTEMI	7.4	4.3	7.5	3.1
Disease extent				
1 VD	64.4	54.6	53.4	51.0
2 VD	25.2	39.0	32.5	31.0
3 VD	10.4	6.4	14.1	18.0

Preliminary Results in Intention-to-Treat Principle Lesion Characteristics

	CF	ROSS	PERFECT		
	Kissing (143)	No kissing (145)	Single (191)	Crush (201)	
Site					
LAD	91.9	88.7	92.1	94.0	
LCX	5.9	8.5	7.3	4.5	
RCA	2.2	2.8	0.5	1.5	
MEDINA *					
1: 0: 0	3.7	8.5	0	0.5	
0: 1: 0	14.1	10.6	0.5	0	
1: 1: 0	45.9	51.1	0	0.5	
1: 1: 1	25.9	20.6	85.3	86.0	
0: 0: 1	0	0	0	0	
1: 0: 1	5.2	5.0	3.1	4.0	
0: 1: 1	5.2	4.3	11.0	9.0	
No. of lesions	1.5 ± 0.8	1.6 ± 0.7	1.7 ± 9	1.8 ± 0.9	
Reported by independen	t physicians in sites		1997 COLLEGE	MEDICINE Medical Ce	

Preliminary Results in Intention-to-Treat Principle **Procedures**

	CROSS		PERFECT	
	Kissing (143)	No kissing (145)	Single (191)	Crush (201)
Radial approach	33.3	34.8	11.5	11.5
DES types				
Cypher	34.8	25.7	61.3	63.0
Taxus (Liberte)	11.0	15.0	1.6	1.5
Endeavor	28.1	31.4	8.4	7.5
Xience, Promus	15.6	16.4	24.6	24.5
Nobori, Biomatrix	5.2	5.7	3.7	3.0
Others	5.2	5.7	0.5	0.5
Stents per lesion	1.6 ± 0.8	1.6 ± 0.8	$\textbf{2.0} \pm \textbf{1.0}$	$\textbf{2.6} \pm \textbf{1.0}$
IVUS in MB	95.6	96.5	95.8	94.5
IVUS in SB	47.4	33.3	80.1	91.0

Preliminary Results in Intention-to-Treat Principle **Procedures**

	CROSS		PERFECT	
	Kissing (143)	No kissing (145)	Single (191)	Crush (201)
Stents in MB	100	100	99.5	100
No.	1.3 ± 0.5	1.3 ± 0.5	$\textbf{1.4}\pm\textbf{0.6}$	1.4 ± 0.5
Length, mm	33.1 ± 13.2	32.6 ± 13.2	$\textbf{36.9} \pm \textbf{15.7}$	37.7 ± 14.8
Size, mm	$\textbf{3.3}\pm\textbf{0.3}$	$\textbf{3.3}\pm\textbf{0.3}$	$\textbf{3.3}\pm\textbf{0.3}$	$\textbf{3.3}\pm\textbf{0.4}$
Stents in SB	3.7	0.7	29.8	96.5
No.	-	-	0.3 ± 0.5	1.0 ± 0.2
Length, mm	-	-	8.9 ± 11.7	20.5 ± 8.1
Provisional T	100	100	79.6	3.5
Crush	0	0	20.4	95.6
Final kissing	92.5	5.0	81.0	97.0
FFR after proc.	52.6	45.4	15.1	0
< 0.8	18.5	23.3	58.6	-

cardiovascular nesearch Foundation

Preliminary Non-adjudicated Results in Intention-to-Treat Principle No Significant Difference

	CROSS		PERFECT	
	Kissing (143)	No kissing (145)	Single (191)	Crush (201)
Months	$\textbf{27.4} \pm \textbf{15.7}$	28.2 ± 15.6	29.9 ± 13.9	$\textbf{28.9} \pm \textbf{14.1}$
Death	2 (1.6)	0	1 (0.5)	3 (1.5)
Cardiac	1	0	1	2
Non-cardiac	1	0	0	1
MI	7 (5.0)	7 (4.9)	18 (9.4)	19 (9.4)
STEMI	0	0	0	1
Non-STEMI	7	7	18	18
Any revasc.	14 (12.1)	9 (7.4)	6 (3.4)	11 (6.2)
TVR	9 (7.8)	5 (4.1)	3 (1.7)	5 (2.2)
TLR	7 (6.0)	4 (3.0)	3 (1.7)	3 (1.6)
Stent thrombosis	0	1 (0.7) late	0	1 (0.5) late
Death, MI or TVR	16 (12.9)	12 (9.0)	22 (11.6)	26 (13.3)

Conclusion

- Patients with SB stenosis enrolled in PERFECT trial had more extensive CAD than those without SB stenosis enrolled in CROSS trial.
- IVUS-guided bifurcation stenting leads to excellent initial and long-term outcomes.
- In patients without SB stenosis, functional SB jail after MB stenting does not occur frequently.
- In contrast, in patients with SB stenosis, functional SB jail after MB stenting is not uncommon.
- Long-term outcomes of all patients adjudicated by independent CEC will be available in 2013.
- The CROSS and PERFECT trials will provide insight into the mechanism of initial and long-term SB compromise with anatomical and functional evaluations.